HRP20100412T1 - Identifikacija površinskih antigena radi dijagnoze i liječenja tumora - Google Patents
Identifikacija površinskih antigena radi dijagnoze i liječenja tumora Download PDFInfo
- Publication number
- HRP20100412T1 HRP20100412T1 HR20100412T HRP20100412T HRP20100412T1 HR P20100412 T1 HRP20100412 T1 HR P20100412T1 HR 20100412 T HR20100412 T HR 20100412T HR P20100412 T HRP20100412 T HR P20100412T HR P20100412 T1 HRP20100412 T1 HR P20100412T1
- Authority
- HR
- Croatia
- Prior art keywords
- tumor
- antigen
- nucleic acid
- expression
- fragment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract 54
- 239000000427 antigen Substances 0.000 title claims abstract 35
- 102000036639 antigens Human genes 0.000 title claims abstract 35
- 108091007433 antigens Proteins 0.000 title claims abstract 35
- 238000003745 diagnosis Methods 0.000 title claims abstract 3
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 28
- 102000039446 nucleic acids Human genes 0.000 claims abstract 22
- 108020004707 nucleic acids Proteins 0.000 claims abstract 22
- 210000004027 cell Anatomy 0.000 claims abstract 21
- 239000012634 fragment Substances 0.000 claims abstract 17
- 239000000203 mixture Substances 0.000 claims abstract 15
- 230000002159 abnormal effect Effects 0.000 claims abstract 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 6
- 239000000523 sample Substances 0.000 claims abstract 6
- 238000011282 treatment Methods 0.000 claims abstract 5
- 238000001514 detection method Methods 0.000 claims abstract 4
- 230000000694 effects Effects 0.000 claims abstract 4
- 239000000032 diagnostic agent Substances 0.000 claims abstract 3
- 229940039227 diagnostic agent Drugs 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims abstract 3
- 229940124597 therapeutic agent Drugs 0.000 claims abstract 3
- 230000001225 therapeutic effect Effects 0.000 claims abstract 3
- 239000012472 biological sample Substances 0.000 claims abstract 2
- 201000011510 cancer Diseases 0.000 claims 11
- 238000000034 method Methods 0.000 claims 7
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 206010061968 Gastric neoplasm Diseases 0.000 claims 4
- 206010019695 Hepatic neoplasm Diseases 0.000 claims 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 4
- 206010029098 Neoplasm skin Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 208000029742 colonic neoplasm Diseases 0.000 claims 4
- 208000014018 liver neoplasm Diseases 0.000 claims 4
- 208000020816 lung neoplasm Diseases 0.000 claims 4
- 208000037841 lung tumor Diseases 0.000 claims 4
- 238000012544 monitoring process Methods 0.000 claims 4
- 208000025402 neoplasm of esophagus Diseases 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 208000023958 prostate neoplasm Diseases 0.000 claims 4
- 208000025421 tumor of uterus Diseases 0.000 claims 4
- 206010046766 uterine cancer Diseases 0.000 claims 4
- 208000024719 uterine cervix neoplasm Diseases 0.000 claims 4
- 150000001413 amino acids Chemical group 0.000 claims 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 230000003321 amplification Effects 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract 5
- 239000000126 substance Substances 0.000 abstract 4
- 108090000695 Cytokines Proteins 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 230000000295 complement effect Effects 0.000 abstract 2
- 230000001461 cytolytic effect Effects 0.000 abstract 2
- 230000008105 immune reaction Effects 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 239000012190 activator Substances 0.000 abstract 1
- 230000030833 cell death Effects 0.000 abstract 1
- 230000009089 cytolysis Effects 0.000 abstract 1
- 239000000824 cytostatic agent Substances 0.000 abstract 1
- 230000001085 cytostatic effect Effects 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 210000002443 helper t lymphocyte Anatomy 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 229960001438 immunostimulant agent Drugs 0.000 abstract 1
- 239000003022 immunostimulating agent Substances 0.000 abstract 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 1
- 239000000411 inducer Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 239000013610 patient sample Substances 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 238000001890 transfection Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
Abstract
Farmaceutska smjesa koja obuhvaća jednu ili više komponenti izabranih iz skupine koja uključuje: (i) protutijelo koje se veže za tumorski antigen, (ii) tumorski antigen ili njegov fragment koji obuhvaćaju barem 6 susjednih aminokiselina, (iii) nukleinska kiselina koja kodira tumorski antigen ili njegov fragment koji obuhvaćaju barem 6 susjednih aminokiselina, (iv) stanica domaćin koja eksprimira tumorski antigen ili njegov fragment koji obuhvaćaju barem 6 susjednih aminokiselina i (v) izolirane komplekse tumorskog antigena ili njegovog fragmenta i molekule HLA, pri čemu tumorski antigen (a) obuhvaća sekvencu aminokiselina prema SEQ ID NO: 10 ili (b) ima sekvencu koju kodira nukleinska kiselina koja je barem 90% identična nukleinskoj kiselini prema SEQ ID NO: 9za liječenje i/ili cijepljenje protiv karcinoma, naznačenog ekspresijom ili abnormalnom ekspresijom tumorskog antigena, pri čemu se radi o karcinomu iz skupine koja uključuje tumor dojki, tumor pluća, tumor jednjaka, tumor kolona, tumor želuca, tumor gušterače, tumor jetre, tumor jajnika, tumor prostate, tumor uha, grla, nosa (ENT tumor), tumor bubrega, tumor grlića maternice, tumor kože i tumor maternice. Patent sadrži još 17 patentnih zahtjeva.
Claims (18)
1. Farmaceutska smjesa koja obuhvaća jednu ili više komponenti izabranih iz skupine koja uključuje:
(i) protutijelo koje se veže za tumorski antigen,
(ii) tumorski antigen ili njegov fragment koji obuhvaćaju barem 6 susjednih aminokiselina,
(iii) nukleinska kiselina koja kodira tumorski antigen ili njegov fragment koji obuhvaćaju barem 6 susjednih aminokiselina,
(iv) stanica domaćin koja eksprimira tumorski antigen ili njegov fragment koji obuhvaćaju barem 6 susjednih aminokiselina i
(v) izolirane komplekse tumorskog antigena ili njegovog fragmenta i molekule HLA,
pri čemu tumorski antigen
(a) obuhvaća sekvencu aminokiselina prema SEQ ID NO: 10 ili
(b) ima sekvencu koju kodira nukleinska kiselina koja je barem 90% identična nukleinskoj kiselini prema SEQ ID NO: 9
za liječenje i/ili cijepljenje protiv karcinoma, naznačenog ekspresijom ili abnormalnom ekspresijom tumorskog antigena, pri čemu se radi o karcinomu iz skupine koja uključuje tumor dojki, tumor pluća, tumor jednjaka, tumor kolona, tumor želuca, tumor gušterače, tumor jetre, tumor jajnika, tumor prostate, tumor uha, grla, nosa (ENT tumor), tumor bubrega, tumor grlića maternice, tumor kože i tumor maternice.
2. Farmaceutska smjesa prema zahtjevu 1, naznačena time što se protutijelo selektivno veže za tumorski antigen, posjeduje aktivnost inhibicije tumora i selektivno je za stanice koje eksprimiraju ili abnormalno eksprimiraju tumorski antigen.
3. Farmaceutska smjesa prema zahtjevu 1, naznačena time što komponente (ii), (iii), (iv) i (v) selektivno povećavaju količinu kompleksa molekule HLA i tumorskog antigena ili njegovog fragmenta.
4. Farmaceutska smjesa prema zahtjevu 1 ili 3, naznačena time što je nukleinska kiselina pod (iii) prisutna u vektoru ekspresije.
5. Farmaceutska smjesa prema zahtjevu 1 ili 3, naznačena time što stanica domaćin izlučuje tumorski antigen ili njegov fragment.
6. Farmaceutska smjesa prema zahtjevu 1 ili 3, naznačena time što stanica domaćin dodatno eksprimira molekulu HLA koja se veže za tumorski antigen ili njegov fragment.
7. Farmaceutska smjesa prema zahtjevu 6, naznačena time što stanica domaćin eksprimira molekulu HLA i/ili tumorski antigen ili njegov fragment na rekombinantni način.
8. Farmaceutska smjesa prema zahtjevu 6, naznačena time što stanica domaćin eksprimira molekulu HLA endogeno.
9. Farmaceutska smjesa prema zahtjevu 1, 3, 6 ili 8, naznačena time što je stanica domaćin, stanica koja prezentira antigen.
10. Farmaceutska smjesa prema zahtjevu 1 ili 2, naznačena time što je protutijelo monoklonsko, himerno ili humanizirano protutijelo ili fragment protutijela.
11. Farmaceutska smjesa prema zahtjevu 1 ili 2, naznačena time što je protutijelo spojeno za terapijsko ili dijagnostičko sredstvo.
12. Postupak postavljanja dijagnoze karcinoma, naznačenog ekspresijom ili abnormalnom ekspresijom tumorskog antigena, koji obuhvaća detekciju:
(i) nukleinske kiseline koja kodira tumorski antigen
i/ili
(ii) tumorski antigen
u biološkom uzorku koji se izolira iz bolesnika,
pri čemu tumorski antigen
(a) obuhvaća sekvencu aminokiselina prema SEQ ID NO: 10 ili
(b) ima sekvencu koju kodira nukleinska kiselina koja je barem 90% identična nukleinskoj kiselini prema SEQ ID NO: 9
pri čemu se radi o karcinomu iz skupine koja uključuje tumor dojki, tumor pluća, tumor jednjaka, tumor kolona, tumor želuca, tumor gušterače, tumor jetre, tumor jajnika, tumor prostate, tumor uha, grla, nosa (ENT tumor), tumor bubrega, tumor grlića maternice, tumor kože i tumor maternice.
13. Postupak određivanja regresije, tijeka ili početka bolesti karcinoma, naznačenog ekspresijom ili abnormalnom ekspresijom tumorskog antigena, gdje postupak obuhvaća praćenje uzorka bolesnika koji boluje od karcinoma ili za kojeg se sumnja na mogući razvoj karcinoma s obzirom na jedan ili više parametara iz skupine koja obuhvaća:
(i) količinu nukleinske kiseline koja kodira tumorski antigen i
(ii) količinu tumorskog antigena,
pri čemu tumorski antigen
(a) obuhvaća sekvencu aminokiselina prema SEQ ID NO: 10 ili
(b) ima sekvencu koju kodira nukleinska kiselina koja je barem 90% identična nukleinskoj kiselini prema SEQ ID NO: 9
pri čemu se radi o karcinomu iz skupine koja uključuje tumor dojki, tumor pluća, tumor jednjaka, tumor kolona, tumor želuca, tumor gušterače, tumor jetre, tumor jajnika, tumor prostate, tumor uha, grla, nosa (ENT tumor), tumor bubrega, tumor grlića maternice, tumor kože i tumor maternice.
14. Postupak prema zahtjevu 13, naznačen time što obuhvaća određivanje parametra ili parametara u prvoj vremenskoj točki u prvom uzorku i u drugoj vremenskoj točki u daljnjem uzorku, pri čemu se tijek karcinoma određuje usporedbom oba uzorka.
15. Postupak prema bilo kojem od zahtjeva 12-14, naznačen time što se na detekciju ili praćenje prema (i) utječe selektivnim umnažanjem nukleinske kiseline ili njezinog fragmenta ili uporabom polinukleotidne probe koja specifično hibridizira s nukleinskom kiselinom.
16. Postupak prema bilo kojem od zahtjeva 12-14, naznačen time što se na detekciju ili praćenje prema (ii) utječe uporabom protutijela koje se specifično veže za tumorski antigen.
17. Uporaba protutijela koje se veže za tumorski antigen i spaja za terapijsko ili dijagnostičko sredstvo radi pripreme farmaceutske smjese za liječenje, dijagnozu ili praćenje karcinoma, naznačenog ekspresijom ili abnormalnom ekspresijom tumorskog antigena, pri čemu tumorski antigen
(a) obuhvaća sekvencu aminokiselina prema SEQ ID NO: 10 ili
(b) ima sekvencu koju kodira nukleinska kiselina koja je barem 90% identična nukleinskoj kiselini prema SEQ ID NO: 9
pri čemu se radi o karcinomu iz skupine koja uključuje tumor dojki, tumor pluća, tumor jednjaka, tumor kolona, tumor želuca, tumor gušterače, tumor jetre, tumor jajnika, tumor prostate, tumor uha, grla, nosa (ENT tumor), tumor bubrega, tumor grlića maternice, tumor kože i tumor maternice.
18. Postupak prema zahtjevu 16 ili uporaba prema zahtjevu 17, naznačeni time što je protutijelo monoklonsko, himerno ili humanizirano protutijelo ili fragment protutijela.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004023187A DE102004023187A1 (de) | 2004-05-11 | 2004-05-11 | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
| PCT/EP2005/005104 WO2005110338A2 (de) | 2004-05-11 | 2005-05-11 | Identifizierung von oberflächen-assoziierten antigenen für die tumordiagnose und -therapie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100412T1 true HRP20100412T1 (hr) | 2010-09-30 |
Family
ID=35064875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100412T HRP20100412T1 (hr) | 2004-05-11 | 2010-07-26 | Identifikacija površinskih antigena radi dijagnoze i liječenja tumora |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US7785801B2 (hr) |
| EP (18) | EP2258867A3 (hr) |
| JP (6) | JP2007537197A (hr) |
| AT (1) | ATE468409T1 (hr) |
| AU (1) | AU2005244425B2 (hr) |
| CA (2) | CA2820168C (hr) |
| DE (2) | DE102004023187A1 (hr) |
| DK (1) | DK1759013T3 (hr) |
| ES (1) | ES2346067T3 (hr) |
| HR (1) | HRP20100412T1 (hr) |
| PL (1) | PL1759013T3 (hr) |
| PT (1) | PT1759013E (hr) |
| SI (1) | SI1759013T1 (hr) |
| WO (1) | WO2005110338A2 (hr) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
| DE102004023187A1 (de) * | 2004-05-11 | 2005-12-01 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| US8535677B2 (en) | 2006-06-06 | 2013-09-17 | Oxford Biotherapeutics, Ltd. | Antibody drug conjugate treatment of colorectal cancer |
| WO2010123874A1 (en) | 2009-04-20 | 2010-10-28 | Oxford Biotherapeutics Ltd. | Antibodies specific to cadherin-17 |
| GB0611116D0 (en) * | 2006-06-06 | 2006-07-19 | Oxford Genome Sciences Uk Ltd | Proteins |
| EP3111955B1 (en) * | 2006-08-14 | 2019-01-23 | Chugai Seiyaku Kabushiki Kaisha | Diagnosis and treatment of cancer using anti-desmoglein-3 antibody |
| DE102007034993A1 (de) * | 2007-07-26 | 2009-01-29 | Hanna Diehl | Lösliches Cadherin 17 für die Diagnose und Risikostratifizierung von Darmtumor oder Darmkrebs |
| KR101517556B1 (ko) * | 2008-06-25 | 2015-05-06 | 재단법인 한국파스퇴르연구소 | Ｈｉｖ－1 감염에 대한 사람 보조인자의 전장 유전체 시각적 동정 |
| JP5371017B2 (ja) * | 2008-10-10 | 2013-12-18 | 独立行政法人放射線医学総合研究所 | 子宮頚部腺癌の診断又は子宮頸癌の予後の診断のためのマーカー |
| SG185027A1 (en) * | 2010-05-03 | 2012-11-29 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
| CA2815041A1 (en) * | 2010-10-20 | 2012-04-26 | Oxford Biotherapeutics Ltd. | Antibodies |
| US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
| RS64230B1 (sr) | 2011-05-24 | 2023-06-30 | BioNTech SE | Individualizovane vakcine protiv kancera |
| CN102311242B (zh) * | 2011-05-27 | 2014-10-01 | 刘长福 | 一种造纸废液生产的水溶性高分子助磨剂及制造方法 |
| KR101314828B1 (ko) * | 2011-09-26 | 2013-10-04 | 한국원자력연구원 | 비소세포성 폐암에서 ｔｍ４ｓｆ４의 발현 또는 활성의 조절을 통한 방사선 저항성 및 암세포의 성장, 전이, 및 침윤능력을 저하시키는 방법 |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| US10988516B2 (en) | 2012-03-26 | 2021-04-27 | Uti Limited Partnership | Methods and compositions for treating inflammation |
| US9603948B2 (en) | 2012-10-11 | 2017-03-28 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
| WO2014082729A1 (en) | 2012-11-28 | 2014-06-05 | Biontech Ag | Individualized vaccines for cancer |
| WO2014180490A1 (en) | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
| EP3065771B1 (en) | 2013-11-04 | 2019-03-20 | UTI Limited Partnership | Methods and compositions for sustained immunotherapy |
| AU2015315005B9 (en) | 2014-09-10 | 2021-08-12 | Genentech, Inc. | Immunogenic mutant peptide screening platform |
| WO2016045732A1 (en) | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
| WO2016128060A1 (en) | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
| JP6492914B2 (ja) | 2015-04-15 | 2019-04-03 | 株式会社デンソー | 光走査装置 |
| CA2980495A1 (en) * | 2015-04-20 | 2016-10-27 | Consejo Superior De Investigaciones Cientificas | Agents binding specifically to human cadherin-17, human cadherin-5, human cadherin-6 and human cadherin-20 rgd motif |
| CA2994951A1 (en) | 2015-08-07 | 2017-02-16 | Imaginab, Inc. | Antigen binding constructs to target molecules |
| WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
| JP6983779B2 (ja) * | 2015-11-30 | 2021-12-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California | 非常に特異的な腫瘍細胞表面抗原を標的とするヒト抗体を用いた腫瘍特異的ペイロード送達及び免疫活性化 |
| KR20180107102A (ko) | 2015-12-16 | 2018-10-01 | 그릿스톤 온콜로지, 인코포레이티드 | 신생항원 동정, 제조, 및 용도 |
| EP3402571A4 (en) | 2016-01-15 | 2019-08-28 | The J. David Gladstone Institutes | METHOD FOR THE TREATMENT OF DISORDERS BY METABOLIC CONTROL OF T-CELL DIFFERENTIATION |
| US11266745B2 (en) | 2017-02-08 | 2022-03-08 | Imaginab, Inc. | Extension sequences for diabodies |
| CN106919801B (zh) * | 2017-03-08 | 2023-07-18 | 杭州大伽信息科技有限公司 | 一种免疫组织化学染色辅助分析系统及使用方法 |
| CA3078744A1 (en) | 2017-10-10 | 2019-04-18 | Gritstone Oncology, Inc. | Neoantigen identification using hotspots |
| CN111630602A (zh) | 2017-11-22 | 2020-09-04 | 磨石肿瘤生物技术公司 | 减少新抗原的接合表位呈递 |
| WO2019183683A1 (en) * | 2018-03-29 | 2019-10-03 | The University Of Newcastle | Diagnostic and prognostic methods for estrogen-induced cancers |
| TW202116332A (zh) * | 2019-06-23 | 2021-05-01 | 大陸商廣東天科雅生物醫藥科技有限公司 | 抗alpp car-t細胞療法 |
| US20230002485A1 (en) * | 2019-12-06 | 2023-01-05 | Korea Atomic Energy Research Institute | Anti-tm4sf4 antibody and uses thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4732847A (en) * | 1981-06-09 | 1988-03-22 | University Of Hawaii | Monoclonal antibodies for DNA-RNA hybrid complexes and their uses |
| US5081227A (en) * | 1988-03-04 | 1992-01-14 | La Jolla Cancer Research Foundation | Germ cell alkaline phosphatase |
| GB9019812D0 (en) | 1990-09-11 | 1990-10-24 | Scotgen Ltd | Novel antibodies for treatment and prevention of infection in animals and man |
| WO1993010813A1 (en) | 1991-11-27 | 1993-06-10 | THE UNITED STAES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Nucleotide and amino acid sequence of pemphigus vulgaris antigen and methods of use |
| US5677139A (en) | 1995-04-21 | 1997-10-14 | President And Fellows Of Harvard College | In vitro differentiation of CD34+ progenitor cells into T lymphocytes |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| PT879282E (pt) | 1996-01-17 | 2003-11-28 | Imp College Innovations Ltd | Imunoterapia utilizando linfocitos t citotoxicos (ctl) |
| EP1144636A2 (en) | 1998-09-28 | 2001-10-17 | Chiron Corporation | Human genes and gene expression products |
| EP1252300B1 (en) * | 2000-02-03 | 2011-01-19 | Dendreon Corporation | Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
| KR100374423B1 (ko) * | 2000-04-25 | 2003-03-28 | 주식회사 아이씨엔지 | 다수의 ｍａｇｅ 아형 또는 ｇａｇｅ 아형을 인식하는암진단용 프라이머 |
| EP1358349A2 (en) * | 2000-06-05 | 2003-11-05 | Avalon Pharmaceuticals | Cancer gene determination and therapeutic screening using signature gene sets |
| ES2284678T3 (es) * | 2000-08-15 | 2007-11-16 | Immunex Corporation | Polipeptidos de claudinas. |
| US6697557B2 (en) * | 2000-10-04 | 2004-02-24 | University Of South Florida | Two-dimensional optical filter and associated methods |
| DE10057894A1 (de) * | 2000-11-22 | 2002-06-06 | Adnagen Gmbh | Diagnose-Kit, DNS-Chip sowie Verfahren zur Diagnostik oder Behandlungskontrolle bei Hodenkrebs |
| EP1463928A2 (en) | 2001-04-18 | 2004-10-06 | Protein Design Labs | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
| WO2003000928A2 (en) * | 2001-06-25 | 2003-01-03 | Buadbo Aps | Methods for identification of cancer cell surface molecules and cancer specific promoters, and therapeutic uses thereof |
| US20040076955A1 (en) * | 2001-07-03 | 2004-04-22 | Eos Biotechnology, Inc. | Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer |
| WO2003018621A2 (en) * | 2001-08-23 | 2003-03-06 | Oxford Biomedica (Uk) Limited | Genes |
| EP1293569A3 (en) * | 2001-09-14 | 2004-03-31 | Research Association for Biotechnology | Full-length cDNAs |
| JP2003088388A (ja) * | 2001-09-14 | 2003-03-25 | Herikkusu Kenkyusho:Kk | 新規な全長ｃＤＮＡ |
| DE10211088A1 (de) * | 2002-03-13 | 2003-09-25 | Ugur Sahin | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| DE10254601A1 (de) * | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| WO2004093788A2 (en) * | 2003-04-17 | 2004-11-04 | The Trustees Of Columbia University In The City Ofnew York | Desmoglein 4 is a novel gene involved in hair growth |
| EP1640452A4 (en) * | 2003-05-30 | 2009-12-23 | Nippon Shinyaku Co Ltd | OLIGOBICATENARY RNA INHIBITING BCL-2 EXPRESSION AND MEDICINAL COMPOSITION CONTAINING THE SAME |
| DE102004023187A1 (de) * | 2004-05-11 | 2005-12-01 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
-
2004
- 2004-05-11 DE DE102004023187A patent/DE102004023187A1/de not_active Withdrawn
-
2005
- 2005-05-11 EP EP10010161A patent/EP2258867A3/de not_active Withdrawn
- 2005-05-11 US US11/596,106 patent/US7785801B2/en active Active
- 2005-05-11 EP EP10010164A patent/EP2287337A3/de not_active Withdrawn
- 2005-05-11 EP EP10010159A patent/EP2275571A3/de not_active Withdrawn
- 2005-05-11 EP EP18157525.9A patent/EP3382036A1/de not_active Withdrawn
- 2005-05-11 EP EP10010158A patent/EP2290103A3/de not_active Withdrawn
- 2005-05-11 DK DK05747772.1T patent/DK1759013T3/da active
- 2005-05-11 EP EP10010155.9A patent/EP2280082B1/de active Active
- 2005-05-11 ES ES05747772T patent/ES2346067T3/es active Active
- 2005-05-11 CA CA2820168A patent/CA2820168C/en active Active
- 2005-05-11 EP EP10005074A patent/EP2239340A3/de not_active Withdrawn
- 2005-05-11 EP EP10010163A patent/EP2258869A3/de not_active Withdrawn
- 2005-05-11 EP EP10010166A patent/EP2267157A3/de not_active Withdrawn
- 2005-05-11 EP EP10010640A patent/EP2275572A3/de not_active Withdrawn
- 2005-05-11 AT AT05747772T patent/ATE468409T1/de active
- 2005-05-11 JP JP2007512091A patent/JP2007537197A/ja active Pending
- 2005-05-11 PL PL05747772T patent/PL1759013T3/pl unknown
- 2005-05-11 EP EP10010168A patent/EP2267158A3/de not_active Withdrawn
- 2005-05-11 EP EP10010165A patent/EP2267156A3/de not_active Withdrawn
- 2005-05-11 CA CA002563671A patent/CA2563671A1/en not_active Abandoned
- 2005-05-11 EP EP05747772A patent/EP1759013B1/de active Active
- 2005-05-11 WO PCT/EP2005/005104 patent/WO2005110338A2/de active Application Filing
- 2005-05-11 AU AU2005244425A patent/AU2005244425B2/en not_active Ceased
- 2005-05-11 DE DE502005009602T patent/DE502005009602D1/de active Active
- 2005-05-11 EP EP10010157A patent/EP2275570A3/de not_active Withdrawn
- 2005-05-11 SI SI200531066T patent/SI1759013T1/sl unknown
- 2005-05-11 EP EP10010160A patent/EP2290104A3/de not_active Withdrawn
- 2005-05-11 EP EP10010162A patent/EP2258868A3/de not_active Withdrawn
- 2005-05-11 EP EP10010167A patent/EP2270209A3/de not_active Withdrawn
- 2005-05-11 EP EP10010156A patent/EP2348135A3/de not_active Withdrawn
- 2005-05-11 PT PT05747772T patent/PT1759013E/pt unknown
-
2010
- 2010-07-26 HR HR20100412T patent/HRP20100412T1/hr unknown
- 2010-08-06 US US12/851,980 patent/US9255131B2/en not_active Expired - Fee Related
-
2011
- 2011-10-18 JP JP2011229287A patent/JP5732369B2/ja not_active Expired - Fee Related
-
2012
- 2012-10-16 JP JP2012228762A patent/JP5796003B2/ja active Active
-
2013
- 2013-09-25 US US14/036,969 patent/US9533043B2/en active Active
-
2014
- 2014-11-28 JP JP2014240820A patent/JP2015083576A/ja active Pending
-
2016
- 2016-01-28 US US15/009,061 patent/US20160193335A1/en not_active Abandoned
- 2016-04-25 JP JP2016086914A patent/JP6434444B2/ja active Active
-
2017
- 2017-08-11 US US15/675,148 patent/US10724103B2/en active Active
-
2018
- 2018-03-09 JP JP2018042560A patent/JP2018104464A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100412T1 (hr) | Identifikacija površinskih antigena radi dijagnoze i liječenja tumora | |
| ES2664386T3 (es) | Identificación de antígenos asociados a tumor para el diagnóstico y la terapia | |
| CN107624118A (zh) | 用于肺癌(包括非小细胞肺癌和其他癌症)免疫治疗的新型肽和肽组合物 | |
| EP3210625A2 (en) | Therapeutic peptides comprising antibodies binding to mhc class 1 polypeptide related sequence a (mica) | |
| JP2007537197A5 (hr) | ||
| JP6244912B2 (ja) | 癌の検出方法 | |
| JP2007506417A5 (hr) | ||
| JP2008537546A5 (hr) | ||
| US8105598B2 (en) | Human monoclonal antibodies that specifically bind IGF-II | |
| JP6244911B2 (ja) | 癌の検出方法 | |
| CN102498219A (zh) | 在得自对象的生物学样品中评价癌症的方法 | |
| CN108003239B (zh) | 一种全人源抗egfr单链抗体及其应用 | |
| CN108129564B (zh) | 一种全人源的抗vegf单链抗体及其应用 | |
| EA005169B1 (ru) | РЕКОМБИНАНТНОЕ АНТИТЕЛО, ВЗАИМОДЕЙСТВУЮЩЕЕ С АНТИГЕННЫМ КОМПЛЕКСОМ IOR C2, Fv- ФРАГМЕНТ УКАЗАННОГО АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JP2012525121A5 (hr) | ||
| ES2303595T3 (es) | Moleculas marcadoras asociadas con tumores pulmonares. | |
| Bright et al. | TPD52: A Novel Vaccine Target for Prostate Cancer | |
| JP2006242869A (ja) | 腫瘍マーカーとしての抗ｎａｓｐ抗体及び抗ｔｍｆ抗体 | |
| MX2008003464A (en) | Identification of tumor-associated antigens for diagnosis and therapy |